Marta Garzón-Benavides
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Marta Garzón-Benavides has a total of 131 co-authors. Here are the top co-authors by number of shared publications:
- Carolina Sousa
Department of Microbiology and Parasitology, Faculty of Pharmacy, University of Seville, Seville, Spain
5 shared publications - Isabel Comino
Department of Microbiology and Parasitology, Faculty of Pharmacy, University of Seville, 41012 Seville, Spain
4 shared publications - Verónica Segura
Department of Microbiology and Parasitology, Faculty of Pharmacy, University of Seville, 41012 Seville, Spain
3 shared publications - Ángela Ruiz-Carnicer
Department of Microbiology and Parasitology, Faculty of Pharmacy, University of Seville, 41012 Seville, Spain
3 shared publications A. Pizarro Moreno
Virgen del Rocío University Hospital
2 shared publications- Aurelio Cayuela
Independent Researcher, Seville, Spain
2 shared publications
Latest Publications
- Open Access
- 2 April 2025
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 61 (11) , 1815-1819
Limitations of Faecal Calprotectin in Detecting Histological Changes and Persistent Villous Atrophy in Patients With Coeliac Disease on a Gluten‐Free Diet
Faecal calprotectin is used to assess intestinal inflammation, but its role in monitoring mucosal healing in coeliac disease is unclear. This study followed 48 adults with coeliac disease on a gluten‐free diet over 12 months, evaluating faecal calprotectin levels in correlation with anti‐transglutaminase antibodies, gluten‐free diet adherence by dietary questionnaires and histology. Although significant histological lesions (Marsh II–III) decreased from 24% to 10%, faecal calprotectin levels fluctuated without correlation to anti‐transglutaminase, adherence or histological remission, and did not differentiate between lesion grades. Our findings underscore faecal calprotectin's unreliability in monitoring mucosal healing in adults with coeliac disease, highlighting the urgent need for alternative biomarkers.
- 2 April 2025
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 61 (11) , 1815-1819
Open AccessLimitations of Faecal Calprotectin in Detecting Histological Changes and Persistent Villous Atrophy in Patients With Coeliac Disease on a Gluten‐Free Diet
Faecal calprotectin is used to assess intestinal inflammation, but its role in monitoring mucosal healing in coeliac disease is unclear. This study followed 48 adults with coeliac disease on a gluten‐free diet over 12 months, evaluating faecal calprotectin levels in correlation with anti‐transglutaminase antibodies, gluten‐free diet adherence by dietary questionnaires and histology. Although significant histological lesions (Marsh II–III) decreased from 24% to 10%, faecal calprotectin levels fluctuated without correlation to anti‐transglutaminase, adherence or histological remission, and did not differentiate between lesion grades. Our findings underscore faecal calprotectin's unreliability in monitoring mucosal healing in adults with coeliac disease, highlighting the urgent need for alternative biomarkers.
- 9 May 2023
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 57 (11) , 1341-1342
Editorial: coeliac disease follow‐up guided by gluten immunogenic peptides—are we there yet? Authors' reply
LINKED CONTENT: This article is linked to Garzón‐Benavides et al papers. To view these articles, visit https://doi.org/10.1111/apt.17417 and https://doi.org/10.1111/apt.17464
- 9 May 2023
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 57 (11) , 1341-1342
Editorial: coeliac disease follow‐up guided by gluten immunogenic peptides—are we there yet? Authors' reply
LINKED CONTENT: This article is linked to Garzón‐Benavides et al papers. To view these articles, visit https://doi.org/10.1111/apt.17417 and https://doi.org/10.1111/apt.17464
- Open Access
Evaluation of the Usefulness of an Automatable Immunoassay for Monitoring Celiac Disease by Quantification of Immunogenic Gluten Peptides in Urine
A gluten-free diet (GFD) is currently the only treatment available for patients with celiac disease (CD). However, adherence to a GFD can be challenging because gluten is present in many foods. A lifelong follow-up of patients with CD must be performed to promote adherence to a GFD and to identify the appearance of symptoms and the associated diseases. Therefore, the development of tools to analyze gluten exposure in these patients is important. This study proposes the development of the first automatable ELISA to monitor adherence to a GFD through the quantification of urine gluten immunogenic peptides (u-GIP). Seven healthy volunteers without suspicion of CD and 23 patients with CD were monitored as part of this study to optimize, validate, and apply this assay. Non-interference was found in the urine matrix, and the recovery percentage for spiked samples was 81–101%. The u-GIP was stable for up to 16 days when the samples were stored at different temperatures. Overall, 100% of the patients had detectable u-GIP at diagnosis (range of 0.39–2.14 ng GIP/mL), which reduced to 27% after 12 months on a GFD. Therefore, this highly sensitive immunoassay would allow the analysis of u-GIP from a large battery of samples in clinical laboratories of specialized healthcare centers.
Open AccessEvaluation of the Usefulness of an Automatable Immunoassay for Monitoring Celiac Disease by Quantification of Immunogenic Gluten Peptides in Urine
A gluten-free diet (GFD) is currently the only treatment available for patients with celiac disease (CD). However, adherence to a GFD can be challenging because gluten is present in many foods. A lifelong follow-up of patients with CD must be performed to promote adherence to a GFD and to identify the appearance of symptoms and the associated diseases. Therefore, the development of tools to analyze gluten exposure in these patients is important. This study proposes the development of the first automatable ELISA to monitor adherence to a GFD through the quantification of urine gluten immunogenic peptides (u-GIP). Seven healthy volunteers without suspicion of CD and 23 patients with CD were monitored as part of this study to optimize, validate, and apply this assay. Non-interference was found in the urine matrix, and the recovery percentage for spiked samples was 81–101%. The u-GIP was stable for up to 16 days when the samples were stored at different temperatures. Overall, 100% of the patients had detectable u-GIP at diagnosis (range of 0.39–2.14 ng GIP/mL), which reduced to 27% after 12 months on a GFD. Therefore, this highly sensitive immunoassay would allow the analysis of u-GIP from a large battery of samples in clinical laboratories of specialized healthcare centers.
- Open Access
- 8 March 2023
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 57 (9) , 993-1003
Clinical utility of urinary gluten immunogenic peptides in the follow‐up of patients with coeliac disease
Summary: Background: Gluten‐free diet (GFD) is the only treatment for patients with coeliac disease (CD)and its compliance should be monitored to avoid cumulative damage.Aims: To analyse gluten exposures of coeliac patients on GFD for at least 24 months using different monitoring tools and its impact on duodenal histology at 12‐month follow‐up and evaluate the interval of determination of urinary gluten immunogenic peptides (u‐GIP) for the monitoring of GFD adherence.Methods: Ninety‐four patients with CD on a GFD for at least 24 months were prospectively included. Symptoms, serology, CDAT questionnaire, and u‐GIP (three samples/visit) were analysed at inclusion, 3, 6, and 12 months. Duodenal biopsy was performed at inclusion and 12 months.Results: At inclusion, 25.8% presented duodenal mucosal damage; at 12 months, this percentage reduced by half. This histological improvement was indicated by a reduction in u‐GIP but did not correlate with the remaining tools. The determination of u‐GIP detected a higher number of transgressions than serology, regardless of histological evolution type. The presence of >4 u‐GIP‐positive samples out of 12 collected during 12 months predicted histological lesion with a specificity of 93%. Most patients (94%) with negative u‐GIP in ≥2 follow‐up visits showed the absence of histological lesions (p < 0.05).Conclusion: This study suggests that the frequency of recurrent gluten exposures, according to serial determination of u‐GIP, could be related to the persistence of villous atrophy and that a more regular follow‐up every 6 months, instead of annually, provides more useful data about the adequate adherence to GFD and mucosal healing.
- 8 March 2023
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 57 (9) , 993-1003
Open AccessClinical utility of urinary gluten immunogenic peptides in the follow‐up of patients with coeliac disease
Summary: Background: Gluten‐free diet (GFD) is the only treatment for patients with coeliac disease (CD)and its compliance should be monitored to avoid cumulative damage.Aims: To analyse gluten exposures of coeliac patients on GFD for at least 24 months using different monitoring tools and its impact on duodenal histology at 12‐month follow‐up and evaluate the interval of determination of urinary gluten immunogenic peptides (u‐GIP) for the monitoring of GFD adherence.Methods: Ninety‐four patients with CD on a GFD for at least 24 months were prospectively included. Symptoms, serology, CDAT questionnaire, and u‐GIP (three samples/visit) were analysed at inclusion, 3, 6, and 12 months. Duodenal biopsy was performed at inclusion and 12 months.Results: At inclusion, 25.8% presented duodenal mucosal damage; at 12 months, this percentage reduced by half. This histological improvement was indicated by a reduction in u‐GIP but did not correlate with the remaining tools. The determination of u‐GIP detected a higher number of transgressions than serology, regardless of histological evolution type. The presence of >4 u‐GIP‐positive samples out of 12 collected during 12 months predicted histological lesion with a specificity of 93%. Most patients (94%) with negative u‐GIP in ≥2 follow‐up visits showed the absence of histological lesions (p < 0.05).Conclusion: This study suggests that the frequency of recurrent gluten exposures, according to serial determination of u‐GIP, could be related to the persistence of villous atrophy and that a more regular follow‐up every 6 months, instead of annually, provides more useful data about the adequate adherence to GFD and mucosal healing.
- 1 November 2020
- Published by Elsevier in The American Journal of Clinical Nutrition
- Vol. 112 (5) , 1240-1251
Negative predictive value of the repeated absence of gluten immunogenic peptides in the urine of treated celiac patients in predicting mucosal healing: new proposals for follow-up in celiac disease
The treatment of celiac disease (CD) is a lifelong gluten-free diet (GFD). The current methods for monitoring GFD conformance, such as a dietary questionnaire or serology tests, may be inaccurate in detecting dietary transgressions, and duodenal biopsies are invasive, expensive, and not a routine monitoring technique. Our aim was to determine the clinical usefulness of urine gluten immunogenic peptides (GIP) as a biomarker monitoring GFD adherence in celiac patients and to evaluate the concordance of the results with the degree of mucosal damage. A prospective observational study was conducted involving 22 de novo CD patients, 77 celiac patients consuming a GFD, and 13 nonceliac subjects. On 3 d of the week, urine samples were collected and the GIP concentrations were tested. Simultaneously, anti-tissue transglutaminase antibodies, questionnaire results, clinical manifestations, and histological findings were analyzed. Approximately 24% (18 of 76) of the celiac patients consuming a GFD exhibited Marsh II-III mucosal damage. Among this population, 94% (17 of 18) had detectable urine GIP; however, between 60% and 80% were asymptomatic and exhibited negative serology and appropriate GFD adherence based on the questionnaire. In contrast, 97% (31 of 32) of the celiac patients without duodenal damage had no detectable GIP. These results demonstrated the high sensitivity (94%) and negative predictive value (97%) of GIP measurements in relation to duodenal biopsy findings. In the de novo CD-diagnosed cohort, 82% (18 of 22) of patients had measurable amounts of GIP in the urine. Determining GIP concentrations in several urine samples may be an especially convenient approach to assess recent gluten exposure in celiac patients and appears to accurately predict the absence of histological lesions. The introduction of GIP testing as an assessment technique for GFD adherence may help in ascertaining dietary compliance and to target the most suitable intervention during follow-up.
- 1 November 2020
- Published by Elsevier in The American Journal of Clinical Nutrition
- Vol. 112 (5) , 1240-1251
Negative predictive value of the repeated absence of gluten immunogenic peptides in the urine of treated celiac patients in predicting mucosal healing: new proposals for follow-up in celiac disease
The treatment of celiac disease (CD) is a lifelong gluten-free diet (GFD). The current methods for monitoring GFD conformance, such as a dietary questionnaire or serology tests, may be inaccurate in detecting dietary transgressions, and duodenal biopsies are invasive, expensive, and not a routine monitoring technique. Our aim was to determine the clinical usefulness of urine gluten immunogenic peptides (GIP) as a biomarker monitoring GFD adherence in celiac patients and to evaluate the concordance of the results with the degree of mucosal damage. A prospective observational study was conducted involving 22 de novo CD patients, 77 celiac patients consuming a GFD, and 13 nonceliac subjects. On 3 d of the week, urine samples were collected and the GIP concentrations were tested. Simultaneously, anti-tissue transglutaminase antibodies, questionnaire results, clinical manifestations, and histological findings were analyzed. Approximately 24% (18 of 76) of the celiac patients consuming a GFD exhibited Marsh II-III mucosal damage. Among this population, 94% (17 of 18) had detectable urine GIP; however, between 60% and 80% were asymptomatic and exhibited negative serology and appropriate GFD adherence based on the questionnaire. In contrast, 97% (31 of 32) of the celiac patients without duodenal damage had no detectable GIP. These results demonstrated the high sensitivity (94%) and negative predictive value (97%) of GIP measurements in relation to duodenal biopsy findings. In the de novo CD-diagnosed cohort, 82% (18 of 22) of patients had measurable amounts of GIP in the urine. Determining GIP concentrations in several urine samples may be an especially convenient approach to assess recent gluten exposure in celiac patients and appears to accurately predict the absence of histological lesions. The introduction of GIP testing as an assessment technique for GFD adherence may help in ascertaining dietary compliance and to target the most suitable intervention during follow-up.
- 1 February 2020
- Published by Elsevier in Clinical Gastroenterology and Hepatology
- Vol. 18 (2) , 368-374.e1
Clinical and Pathological Characterization of Lynch-Like Syndrome
- 1 February 2020
- Published by Elsevier in Clinical Gastroenterology and Hepatology
- Vol. 18 (2) , 368-374.e1
Clinical and Pathological Characterization of Lynch-Like Syndrome
- 1 January 2019
- Published by Sociedad Espanola de Patologia Digestiva (SEPD) in Revista Española de Enfermedades Digestivas
- Vol. 111 (7) , 568-570
Pancreatobiliary maljunction: association with gallbladder cancer
Background: Pancreatobiliary maljunction is a rare disease characterized by the junction of the pancreatic and biliary ducts outside of the duodenal wall, which normally results in a large common duct. As a result, there is a greater risk of acute pancreatitis and cancer of the gallbladder and biliary tract. Case report: We present the case of a 43-year-old female diagnosed with a pancreatobiliary maljunction and an associated stenosis of the bile duct, secondary to an episode of acute pancreatitis. She underwent several endoscopic retrograde cholangiopancreatography procedures over the course of three years, without improvement of the stenosis, and therefore a surgical approach was taken. Prior to the surgical intervention, magnetic resonance imaging showed the presence of an 11-mm polyp in the gallbladder. A histological study of the surgical sample identified intramucosal adenocarcinoma over a tubular adenoma of the gallbladder. Discussion: Pancreatobiliary maljunction can be considered as a premalignant entity due to the risk of developing cancer of the biliary tree and gallbladder. Therefore, these patients should undergo a prophylactic intervention, despite being asymptomatic.
- 1 January 2019
- Published by Sociedad Espanola de Patologia Digestiva (SEPD) in Revista Española de Enfermedades Digestivas
- Vol. 111 (7) , 568-570
Pancreatobiliary maljunction: association with gallbladder cancer
Background: Pancreatobiliary maljunction is a rare disease characterized by the junction of the pancreatic and biliary ducts outside of the duodenal wall, which normally results in a large common duct. As a result, there is a greater risk of acute pancreatitis and cancer of the gallbladder and biliary tract. Case report: We present the case of a 43-year-old female diagnosed with a pancreatobiliary maljunction and an associated stenosis of the bile duct, secondary to an episode of acute pancreatitis. She underwent several endoscopic retrograde cholangiopancreatography procedures over the course of three years, without improvement of the stenosis, and therefore a surgical approach was taken. Prior to the surgical intervention, magnetic resonance imaging showed the presence of an 11-mm polyp in the gallbladder. A histological study of the surgical sample identified intramucosal adenocarcinoma over a tubular adenoma of the gallbladder. Discussion: Pancreatobiliary maljunction can be considered as a premalignant entity due to the risk of developing cancer of the biliary tree and gallbladder. Therefore, these patients should undergo a prophylactic intervention, despite being asymptomatic.
- 4 April 2017
- Published by Elsevier in Thrombosis Research
- Vol. 154, 55-58
Clinically relevant bleeding and thrombotic events in non-cirrhotic splanchnic vein thrombosis. Long-term follow up
- 4 April 2017
- Published by Elsevier in Thrombosis Research
- Vol. 154, 55-58
Clinically relevant bleeding and thrombotic events in non-cirrhotic splanchnic vein thrombosis. Long-term follow up
- 6 October 2012
- Published by Elsevier in Medicina Clinica
- Vol. 139 (8) , 369-370
Tratamiento con talidomida asociada a procedimiento endoscópico con argón plasma coagulado en la hemorragia rectal por lesiones vasculares secundarias a proctitis actínica grave
- 6 October 2012
- Published by Elsevier in Medicina Clinica
- Vol. 139 (8) , 369-370
Tratamiento con talidomida asociada a procedimiento endoscópico con argón plasma coagulado en la hemorragia rectal por lesiones vasculares secundarias a proctitis actínica grave
- 1 September 2012
- Published by Elsevier in Revista Clínica Española
- Vol. 212 (8) , 416-418
Papel del tratamiento endovascular en la isquemia mesentérica crónica
- 1 September 2012
- Published by Elsevier in Revista Clínica Española
- Vol. 212 (8) , 416-418
Papel del tratamiento endovascular en la isquemia mesentérica crónica